Cooper Labs is soliciting Rorer Group proxies.

Cooper Laboratories announced that it is soliciting the proxies for Rorer’s April 23 annual meeting in support of a resolution requesting Rorer’s directors to get rid of the “poison pill” share-purchase rights adopted by Rorer’s board Feb 7. In its letter to Rorer stockholders, Palo Alto-based Cooper stated that “Rorer’s board, in our view, has unilaterally restricted your freedom, and that of other Rorer shareholders, to decide for yourselves whether to sell your shares in a tender offer.” Cooper now owns 1.06 million Rorer shares, about 4.96% of the shares outstanding.